Literature DB >> 12592323

A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases.

H Hasle1, C M Niemeyer, J M Chessells, I Baumann, J M Bennett, G Kerndrup, D R Head.   

Abstract

Myelodysplastic and myeloproliferative disorders are rare in childhood and there is no widely accepted system for their diagnosis and classification. We propose minimal diagnostic criteria and a simple classification scheme which, while based on accepted morphological features and conforming with the recent suggestions of the WHO, allows for the special problems of myelodysplastic diseases in children. The classification recognizes three major diagnostic groups: (1) juvenile myelomonocytic leukemia (JMML), previously named chronic myelomonocytic leukemia (CMML) or juvenile chronic myeloid leukemia (JCML); (2) myeloid leukemia of Down syndrome, a disease with distinct clinical and biological features, encompassing both MDS and AML occurring in Down syndrome; and (3) MDS occurring both de novo and as a complication of previous therapy or pre-existing bone marrow disorder (secondary MDS). The main subtypes of MDS are refractory cytopenia (RC) and refractory anemia with excess of blasts (RAEB). It is suggested retaining the subtype of RAEB-T with 20-30% blasts in the marrow until more data are available. Cytogenetics and serial assessments of the patients are essential adjuncts to morphology both in diagnosis and classification.

Entities:  

Mesh:

Year:  2003        PMID: 12592323     DOI: 10.1038/sj.leu.2402765

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  72 in total

1.  Third International Symposium on Myelodysplastic Syndromes in Childhood.

Authors:  Atsushi Manabe; Yoshitoshi Ohtsuka
Journal:  Int J Hematol       Date:  2003-12       Impact factor: 2.490

2.  Response to comments from Drs. Alter and Rosenberg.

Authors:  Yigal Dror; Michaela Cada
Journal:  Haematologica       Date:  2015-09       Impact factor: 9.941

3.  Myelodysplastic features in an infant with cystic fibrosis presenting with anaemia, oedema and failure to thrive.

Authors:  Christian Peter Kratz; Tim Rogge; Matthias Kopp; Irith Baumann; Charlotte Marie Niemeyer
Journal:  Eur J Pediatr       Date:  2004-10-23       Impact factor: 3.183

Review 4.  Topics in pediatric leukemia--myelodysplastic and myeloproliferative disorders of childhood.

Authors:  Joseph Lasky; Kathleen M Sakamoto
Journal:  MedGenMed       Date:  2005-03-14

5.  Cytogenetic findings at Down syndrome and their correlation with clinical findings.

Authors:  Amra Catović; Sulejman Kendić
Journal:  Bosn J Basic Med Sci       Date:  2005-11       Impact factor: 3.363

Review 6.  Evolution of myeloid leukemia in children with Down syndrome.

Authors:  Satoshi Saida
Journal:  Int J Hematol       Date:  2016-02-24       Impact factor: 2.490

Review 7.  Malignancy in children with trisomy 21.

Authors:  Karen R Rabin; James A Whitlock
Journal:  Oncologist       Date:  2009-01-28

8.  Granulocytic sarcoma presenting with severe adenopathy (cervical lymph nodes, tonsils, and adenoids) in a child with juvenile myelomonocytic leukemia and successful treatment with allogeneic bone marrow transplantation.

Authors:  Toshihiko Imamura; Satoshi Matsuo; Takao Yoshihara; Tomohiro Chiyonobu; Kanako Mori; Hiroyuki Ishida; Yasutaka Nishimura; Yasuo Kasubuchi; Mayumi Naya; Akira Morimoto; Shigeyoshi Hibi; Shinsaku Imashuku
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

9.  Clinicopathological characteristics of erythroblast-rich RAEB and AML M6a in children.

Authors:  Yuko Honda; Atsushi Manabe; Masahiro Tsuchida; Yuji Zaike; Atsuko Masunaga; Masami Inoue; Ryoji Kobayashi; Yoshitoshi Ohtsuka; Akira Kikuchi; Tatsutoshi Nakahata
Journal:  Int J Hematol       Date:  2008-10-28       Impact factor: 2.490

Review 10.  Constitutional aneuploidy and cancer predisposition.

Authors:  Ithamar Ganmore; Gil Smooha; Shai Izraeli
Journal:  Hum Mol Genet       Date:  2009-04-15       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.